Cancer News
Longer Life, at Any Cost?

Cord Blood Transplant: In Children, One Will Do

Should PIK3CA Inform Therapy Choice in Breast Cancer?

Now Canada Says Don't Use PSA Test for Cancer Screening

Obesity Linked to Worst Outcomes in Children With ALL
Clinical practice guidelines address multimodality treatment for esophageal cancer

New technology shows promise for delivery of therapeutics to the brain

Solution to 14-year mystery has implications for cancer therapies and drug delivery

Improved understanding of glioma may lead to more efficient and specific therapies

Improved understanding of glioma may lead to more efficient and specific therapies
Can Lots of Sex Protect the Prostate?

Is Milk Your Friend or Foe?

Obese Children With Leukemia Fared Worse in Study

Obese Children With Leukemia Fared Worse in Study

'Prehabilitation' Before Colon Cancer Surgery May Aid Recovery
New Discovery by UCLA Researchers Could Lead to More Targeted Head and Neck Cancer Therapies

Patient Profile: Liana's Looms of Love

UCLA Vice Chancellor for Research Elected to Institute of Medicine

UCLA Cancer Researcher Receives Prestigious Innovator Award for Developing New Ways to Use Blood Stem Cells to Attack Cancer

Leading-Edge Lung Cancer Treatment Advances with $1M Grant to UCLA Scientists
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial

A phase III trial of high-dose interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine DTIC, plus interleukin-2 and interferon in patients with high-risk melanoma—an intergroup study of cancer and leukemia group B, Children’s Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: An open-label, phase 2 trial

Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells

Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: Study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel